China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Address: 1715,CHINA WORLD TOWER 1
No. 1 JIAN GUO MEN WAI AVENUE
100004 BEIJING
China (PRC)
Tel: +86 10 65052280
Web: http://www.solvayasiapacific.com/EN/SolvayInAsiaPacific/china/china.aspx
Solvay S.A. is a Belgian chemical and pharmaceutical company. It was founded in 1863 by Ernest Solvay to produce sodium carbonate by the solvay process. Since then the company has diversified to three major sectors of activity: pharmaceuticals, chemicals and plastics.
Solvay (Shanghai) Co., Ltd., a wholly owned subsidiary of Solvay in China is a marketing and sales operations of the main office. The pharmaceutical branch started their operations 11 years ago and currently has more than 200 employees, respectively, in Beijing, Shanghai, Guangzhou and Nanjing.
Pharmaceuticals
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…